A manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply obligations. Following allegations from its partners that the manufacturer was using the patent settlements to adversely affect competition, CRA’s analysis demonstrated that there was no anticompetitive effect and that the supply agreements enhanced efficiency and competition, particularly when considering the Drug Enforcement Agency’s quota system for active ingredient supply for Schedule II products.
CRA experts win prestigious 2026 Antitrust Writing Awards
The awards recognize outstanding scholarship and advocacy in antitrust law and economics. Christian Michel, a principal in the Antitrust & Competition...